Combining tissue profiling with whole
transcriptome spatial analysis and high-plex protein co-detection
enables a deeper, more holistic understanding of tissue
organization
PLEASANTON, Calif., May 24, 2023
/PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in
single cell and spatial biology, announced today the commercial
availability of a new Visium CytAssist Gene and Protein Expression
product to expand the breadth of the Visium CytAssist spatial
analysis capabilities.
"The continued expansion of our Visium platform is a testament
to the strength of our innovation engine and demonstrated
leadership in spatial biology," said Michael Schnall-Levin, Founding Scientist and
Chief Technology Officer. "This launch complements our focus on
multiomic analysis and broader protein capabilities on all three of
our leading platforms, including single cell and in situ
analysis."
Visium CytAssist Gene and Protein Expression enables
researchers to simultaneously produce highly multiplexed protein
and whole transcriptome RNA data mapped together from the same
formalin-fixed, paraffin-embedded (FFPE) tissue section at high
spatial resolution. The Human Immune Cell Profiling Panel is an
optimized, pre-titrated solution that enables the detection of 31
intracellular and extracellular proteins and includes isotype
controls for in-line normalization.
Visium's unique morphology-first workflow allows for H&E
staining upstream of chemical treatments made to the tissue
section. This allows researchers to study the morphology of their
tissue on the same section they also use for deeper spatial
multiomic exploration, allowing for three dimensions of spatial
analysis on the exact same sample.
"We are excited to leverage the CytAssist Gene and Protein
Expression solution to generate more complete assessments of
protein, RNA, and morphology together on each and every tissue
section," said Dr. David Gate,
Assistant Professor of Neurology at Northwestern University. "Spatial transcriptomics
with immune cell profiling at the protein level is transforming our
understanding of complex biological processes in neurodegenerative
disease with great potential to provide new insights into
Alzheimer's disease pathology."
About CytAssist Gene and Protein Expression
Visium
CytAssist Gene and Protein Expression enables combined capture of
protein and whole transcriptome gene expression simultaneously with
histological analysis in one experiment, from a single tissue
section, using a sequencing based readout. The new kit, which is
exclusively available for use with Visium CytAssist, is now
shipping.
Visium CytAssist is a compact, benchtop system designed to
enable the rapid transfer of transcriptomic probes from tissues on
standard microscope slides to Visium slides. The instrument,
launched in 2022, streamlines the Visium workflow by allowing
expanded sample access, simplifying sample handling and improving
data quality for spatial transcriptomic studies.
About 10x Genomics
10x Genomics is a life science
technology company building products to interrogate, understand and
master biology to advance human health. Our integrated solutions
include instruments, consumables and software for analyzing
biological systems at a resolution and scale that matches the
complexity of biology. 10x Genomics products have been adopted by
researchers around the world including in all of the top 100 global
research institutions as ranked by Nature in 2021 based on
publications and all of the top 20 global pharmaceutical companies
by 2021 research and development spend and have been cited in over
5,000 research papers on discoveries ranging from oncology to
immunology and neuroscience. Our patent portfolio comprises more
than 1,750 issued patents and patent applications.
Forward Looking Statements
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 as contained in Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, which are subject
to the "safe harbor" created by those sections. All statements,
other than statements of historical facts, may be forward-looking
statements. Forward-looking statements generally can be identified
by the use of forward-looking terminology such as "may," "might,"
"will,""enable," "should," "expect," "plan," "anticipate," "could,"
"intend," "target," "project," "contemplate," "believe,"
"estimate," "predict," "potential," "would," "likely," "seek" or
"continue" or the negatives of these terms or variations of them or
similar terminology, but the absence of these words does not mean
that a statement is not forward-looking. These forward-looking
statements include statements regarding 10x Genomics, Inc.'s
expectations regarding the continued expansion of our Visium
platform and our product momentum and progress, including the
performance of Visium's unique morphology-first workflow. These
statements are based on management's current expectations,
forecasts, beliefs, assumptions and information currently available
to management, and actual outcomes and results could differ
materially from these statements due to a number of factors. The
material risks and uncertainties that could affect 10x Genomics,
Inc.'s financial and operating results and cause actual results to
differ materially from those indicated by the forward-looking
statements made in this press release include those discussed under
the captions "Risk Factors" and "Management's Discussion and
Analysis of Financial Condition and Results of Operations" in the
company's most recently-filed 10-K and elsewhere in the documents
10x Genomics, Inc. files with the Securities and Exchange
Commission from time to time.
Although 10x Genomics, Inc. believes that the expectations
reflected in the forward-looking statements are reasonable, it
cannot provide any assurance that these expectations will prove to
be correct nor can it guarantee that the future results, levels of
activity, performance and events and circumstances reflected in the
forward-looking statements will be achieved or occur. These
forward-looking statements do not reflect the potential impact of
any future acquisitions, mergers, dispositions, joint ventures or
investments 10x Genomics, Inc. may make. Further, such
forward-looking statements may not accurately or fully reflect the
potential impact of adverse geopolitical and macroeconomic events,
difficulties selling in APAC, product capabilities and adoption
rates, international economic, political, legal, compliance, social
and business factors, such as the COVID-19 pandemic, inflation,
supply chain that may have on the business, financial condition,
results of operations and cash flows of 10x Genomics, Inc. The
forward-looking statements in this press release are based on
information available to 10x Genomics, Inc. as of the date hereof,
and 10x Genomics, Inc. disclaims any obligation to update any
forward-looking statements provided to reflect any change in our
expectations or any change in events, conditions, or circumstances
on which any such statement is based, except as required by law.
These forward-looking statements should not be relied upon as
representing 10x Genomics, Inc.'s views as of any date subsequent
to the date of this press release.
Disclosure Information
10x Genomics, Inc. uses filings
with the Securities and Exchange Commission, our website
(www.10xgenomics.com), press releases, public conference calls,
public webcasts and our social media accounts as means of
disclosing material non-public information and for complying with
our disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/10x-genomics-launches-visium-cytassist-gene-and-protein-expression-assay-301833960.html
SOURCE 10x Genomics, Inc.